Medical Developments International Limited (ASX:MVP)

Market Cap	49.57M -29.0%
Revenue (ttm)	42.57M +9.0%
Net Income	626.00K +566.0%
EPS	0.01 +562.4%
Shares Out	112.66M
PE Ratio	83.03
Forward PE	35.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,533
Open	0.4400
Previous Close	0.4400
Day's Range	0.4400 - 0.4550
52-Week Range	0.3650 - 0.5920
Beta	1.62
Analysts	n/a
Price Target	2.30 (+422.73%)
Est. Earnings	Nov 18, 2026

About ASX:MVP

Medical Developments International Limited provides emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The company also supplies respiratory products, including space chambers, peak flow meters, portable nebulizers...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1972
• Employees: 68
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MVP

Financial Performance

In fiscal year 2026, ASX:MVP's revenue was 42.57 million, an increase of 8.99% compared to the previous year's 39.06 million. Earnings were 626,000, an increase of 565.96%.

Analyst Summary

The average 12-month stock price target for MVP is $2.30, which is an increase of 422.73% from the latest price.

Price Target

$2.30

(422.73% upside)

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error